DWTX vs EDIT

Dogwood Therapeutics, Inc. vs Editas Medicine, Inc. — Valuation Comparison 2026

DWTX

Biotechnology
Dogwood Therapeutics, Inc.
Quality
3.6
out of 10
Value Trap
37
LOW
Price
$1.67
Last close
Models
7/13
Active
VS

EDIT

Biotechnology
Editas Medicine, Inc.
Quality
6.5
out of 10
Value Trap
18
SAFE
Price
$3.43
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType DWTX Fair ValueDWTX Upside EDIT Fair ValueEDIT Upside
Bayesian DCF Intrinsic $0.56 -61.9% $1.15 -66.4%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.05 -96.7% $1.32 -61.6%
Dynamic NAV Asset-Based $0.69 -52.6% $1.28 -62.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for DWTX vs EDIT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DWTX vs EDIT — Which Stock Is More Undervalued?

EDIT scores higher with a 6.5/10 quality rating vs DWTX's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Dogwood Therapeutics, Inc. (DWTX) and Editas Medicine, Inc. (EDIT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DWTX currently trades at $1.67 with a QOC of 3.6/10, while EDIT trades at $3.43 with a QOC of 6.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).